期刊
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
卷 10, 期 8, 页码 -出版社
COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/cshperspect.a036863
关键词
-
资金
- National Institutes of Health [CCSG CA016672, R01 CA211615, U01 CA201777]
- Cancer Prevention & Research Institute of Texas (MIRA) [RP160710]
- National Breast Cancer Foundation, Inc.
- Breast Cancer Research Foundation [BCRF-17-069]
- Patel Memorial Breast Cancer Endowment Fund
- University of Texas MD Anderson-China Medical University
- Hospital Sister Institution Fund
- Center for Biological Pathways
- Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence [MOH W108-TDU-B-212-122015, MOHW108-TDU-B-212-124024]
- Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence (Inha University Institution Fund)
Metastasis, which occurs when cancer cells disseminate from the primary tumor site to other parts of the body, is the primary cause of mortality in patients, and the recurrence of multiple metastatic tumors is an obstacle to eliminating cancer. Recent clinical studies demonstrated that patients who respond to immunotherapy have longer survival rates with lower metastatic relapse, suggesting that immunotherapy may be one of the solutions to overcome cancer metastasis. Indeed, various host immune cells not only shape the tumor microenvironment but also participate in multiple stages of metastasis. Therefore, to improve clinical outcome, it is critical to understand the immunological events associated with tumor development and progression. In this article, we summarize those events that are involved in tumor progression and discuss immunotherapies that can potentially target cancer metastasis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据